Phase II evaluation of maytansine (NSC 153858) in advanced cancer. A Southeastern Cancer Study Group trial.
Maytansine given in a 3-day course q3 weeks produced only five responses (3%) in 163 evaluable adults with advanced cancer. The dose schedule employed is not recommended for further study.